A new study by MSK’s Dr. Neil Iyengar and colleagues published in JAMA Oncology finds that women with normal BMIs but high levels of overall body fat are at an increased risk for invasive breast cancer. The cohort study followed 3,460 postmenopausal women for a median 16.4 years. Researchers measured body fat using Dual-energy X-ray absorptiometry five times throughout the course of the study. They concluded that for each five kilogram increase in trunk fat, women had a 56% increase in risk of developing estrogen-receptor (ER) positive breast cancers, even when BMI remained in the healthy range.

Learn more about this study:
MediBulletin
MedicalResearch.com
MedPage Today

Last week, the Food and Drug Administration (FDA) for the first time approved a cancer drug, larotrectinib (Vitrakvi), based on a genetic mutation rather than type of cancer. The FDA’s approval drew on the findings of three clinical trials comprised of 55 patients, the results of which were compiled and reported in the New England Journal of Medicine by MSK’s Dr. David Hyman, Dr. Alexander Drilon, and collaborators.

The NTRK gene fusion mutation can only be identified through broad genetic tumor testing. While the mutation occurs in less than one percent of solid tumors, it has been identified in dozens of often rare tumor types in adults and children. In the three trials, patients given the drug had a 75% overall response rate.

Learn More:
OncLive
Washington Post
MSK On Cancer blog  

Two recent articles in major news outlets feature MSK’s Dr. Peter Bach discussing drug costs.

A Washington Post article considers alternate methods for calculating drug prices, including “value-based pricing.” Dr. Bach comments that such a system would “anchor a drug’s price to its benefit,” but that the benefit would have to be very clearly defined. Later in the article, Dr. Bach states that it is difficult to determine which aspects of drugs should be valued most and thus become factors in both cost and drug development priorities in a value-based pricing system.

A New York Times article takes a historical view of rising drug costs. U.S. drug spending tripled from 1997 to 2007, then plateaued for about six years before rising again. Dr. Bach explains that the more recent price hikes are due in part to a lack of competition for new biologic drugs and quicker FDA approvals for new, expensive pharmaceuticals.